OTCMKTS:ARGSQ

Argos Therapeutics Competitors

$0.05
+0.01 (+19.11 %)
(As of 09/24/2019)
Add
Compare
Today's Range
$0.04
Now: $0.05
$0.05
50-Day Range
$0.05
MA: $0.05
$0.05
52-Week Range
$0.02
Now: $0.05
$0.25
Volume7,500 shs
Average Volume13,394 shs
Market Capitalization$567,463.20
P/E RatioN/A
Dividend YieldN/A
Beta2.47

Competitors

Argos Therapeutics (OTCMKTS:ARGSQ) Vs. NSPX, VVUSQ, IMUCD, CAPS, WWHC, and IMUC

Should you be buying ARGSQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Argos Therapeutics, including Inspyr Therapeutics (NSPX), VIVUS (VVUSQ), ImmunoCellular Therapeutics (IMUCD), Capstone Therapeutics (CAPS), W World (WWHC), and ImmunoCellular Therapeutics (IMUC).

Argos Therapeutics (OTCMKTS:ARGSQ) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Argos Therapeutics and Inspyr Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Argos Therapeutics0000N/A
Inspyr Therapeutics0000N/A

Volatility & Risk

Argos Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, meaning that its stock price is 1,755% less volatile than the S&P 500.

Valuation & Earnings

This table compares Argos Therapeutics and Inspyr Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argos Therapeutics$1.90 million0.30$-40,570,000.00N/AN/A
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A

Inspyr Therapeutics has lower revenue, but higher earnings than Argos Therapeutics.

Profitability

This table compares Argos Therapeutics and Inspyr Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Argos TherapeuticsN/AN/AN/A
Inspyr TherapeuticsN/AN/A-298.11%

Summary

Argos Therapeutics beats Inspyr Therapeutics on 3 of the 4 factors compared between the two stocks.

VIVUS (OTCMKTS:VVUSQ) and Argos Therapeutics (OTCMKTS:ARGSQ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for VIVUS and Argos Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVUS0000N/A
Argos Therapeutics0000N/A

Risk & Volatility

VIVUS has a beta of -3.25, suggesting that its share price is 425% less volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500.

Valuation and Earnings

This table compares VIVUS and Argos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04
Argos Therapeutics$1.90 million0.30$-40,570,000.00N/AN/A

VIVUS has higher revenue and earnings than Argos Therapeutics.

Profitability

This table compares VIVUS and Argos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVUS-39.28%N/A-12.18%
Argos TherapeuticsN/AN/AN/A

Insider & Institutional Ownership

7.3% of VIVUS shares are owned by institutional investors. 12.0% of VIVUS shares are owned by insiders. Comparatively, 28.2% of Argos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Argos Therapeutics beats VIVUS on 5 of the 8 factors compared between the two stocks.

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) and Argos Therapeutics (OTCMKTS:ARGSQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Profitability

This table compares ImmunoCellular Therapeutics and Argos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoCellular TherapeuticsN/AN/AN/A
Argos TherapeuticsN/AN/AN/A

Risk and Volatility

ImmunoCellular Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ImmunoCellular Therapeutics and Argos Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoCellular Therapeutics0000N/A
Argos Therapeutics0000N/A

Valuation & Earnings

This table compares ImmunoCellular Therapeutics and Argos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A
Argos Therapeutics$1.90 million0.30$-40,570,000.00N/AN/A

ImmunoCellular Therapeutics has higher earnings, but lower revenue than Argos Therapeutics.

Summary

Argos Therapeutics beats ImmunoCellular Therapeutics on 2 of the 3 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and Argos Therapeutics (OTCMKTS:ARGSQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Volatility & Risk

Capstone Therapeutics has a beta of 176.15, suggesting that its stock price is 17,515% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 2.47, suggesting that its stock price is 147% more volatile than the S&P 500.

Profitability

This table compares Capstone Therapeutics and Argos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Capstone TherapeuticsN/AN/AN/A
Argos TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Capstone Therapeutics and Argos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$2 million0.92$-380,000.00N/AN/A
Argos Therapeutics$1.90 million0.30$-40,570,000.00N/AN/A

Capstone Therapeutics has higher revenue and earnings than Argos Therapeutics.

Analyst Ratings

This is a summary of recent ratings for Capstone Therapeutics and Argos Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Capstone Therapeutics0000N/A
Argos Therapeutics0000N/A

Insider & Institutional Ownership

2.6% of Capstone Therapeutics shares are owned by institutional investors. 42.8% of Capstone Therapeutics shares are owned by insiders. Comparatively, 28.2% of Argos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Capstone Therapeutics beats Argos Therapeutics on 6 of the 6 factors compared between the two stocks.

Argos Therapeutics (OTCMKTS:ARGSQ) and W World (OTCMKTS:WWHC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Argos Therapeutics and W World's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Argos TherapeuticsN/AN/AN/A
W WorldN/AN/AN/A

Risk & Volatility

Argos Therapeutics has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500. Comparatively, W World has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Valuation & Earnings

This table compares Argos Therapeutics and W World's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argos Therapeutics$1.90 million0.30$-40,570,000.00N/AN/A
W WorldN/AN/AN/AN/AN/A

W World has lower revenue, but higher earnings than Argos Therapeutics.

Analyst Ratings

This is a summary of current recommendations and price targets for Argos Therapeutics and W World, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Argos Therapeutics0000N/A
W World0000N/A

Institutional & Insider Ownership

0.1% of W World shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by company insiders. Comparatively, 61.1% of W World shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Argos Therapeutics (OTCMKTS:ARGSQ) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Argos Therapeutics and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Argos TherapeuticsN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/AN/A

Volatility & Risk

Argos Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Valuation & Earnings

This table compares Argos Therapeutics and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argos Therapeutics$1.90 million0.30$-40,570,000.00N/AN/A
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A

ImmunoCellular Therapeutics has lower revenue, but higher earnings than Argos Therapeutics.

Analyst Ratings

This is a summary of current recommendations and price targets for Argos Therapeutics and ImmunoCellular Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Argos Therapeutics0000N/A
ImmunoCellular Therapeutics0000N/A

Summary

Argos Therapeutics beats ImmunoCellular Therapeutics on 2 of the 2 factors compared between the two stocks.


Argos Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NSPX
Inspyr Therapeutics
0.5$0.01+2.0%$2.21 millionN/A0.00
VVUSQ
VIVUS
0.6$0.12+1.5%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.31+11.3%$2.10 millionN/A0.00Gap Down
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$34.00+5.9%$1.84 million$2 million0.00Gap Down
WWHC
W World
0.8$6.09+4.8%$1.80 millionN/A0.00High Trading Volume
Gap Up
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.50+25.8%$1.76 millionN/A0.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.10+4.8%$1.67 million$710,000.000.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03+7.0%$1.54 million$530,000.000.00Gap Down
MLNTQ
Melinta Therapeutics
0.2$0.11+7.9%$1.51 million$96.43 million0.00Gap Up
Achaogen logo
AKAOQ
Achaogen
0.6$0.02+12.2%$1.30 million$8.73 million0.00
AOLS
Aeolus Pharmaceuticals
0.8$0.01+15.4%$1.19 millionN/A0.00Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05+388.2%$1.12 millionN/A-0.57Upcoming Earnings
High Trading Volume
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.24+4.8%$1.12 millionN/A0.00
ATRX
Adhera Therapeutics
0.0$0.09+17.6%$1.11 million$250,000.000.00Gap Up
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04+14.9%$1.08 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.01+1.4%$1.05 millionN/A0.00
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.05+16.9%$1.03 millionN/A0.00Gap Down
SPHS
Sophiris Bio
0.1$0.03+8.8%$1.01 millionN/A0.00Gap Down
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07+11.0%$996,000.00N/A0.00Gap Down
PXYN
Praxsyn
0.6$0.00+25.0%$848,000.00N/A0.00Gap Up
STLT
Spotlight Innovation
0.5$0.02+55.6%$772,000.00N/A0.00Gap Down
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03+29.2%$771,000.00N/A0.00
SKVI
Skinvisible
0.7$0.15+0.0%$671,000.00$40,000.000.00
TRPXD
Therapix Biosciences
0.0$5.98+51.8%$454,000.00N/A0.00Gap Up
BSPM
Biostar Pharmaceuticals
0.0$0.17+12.1%$436,000.00N/A0.00Gap Up
HSTC
HST Global
0.8$0.07+108.3%$378,000.00N/A0.00High Trading Volume
Gap Down
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02+25.3%$366,000.00N/A0.00Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47+3.7%$338,000.00$36.55 million0.00Gap Up
WDBG
Woodbrook Group
0.0$1.48+14.2%$207,000.00N/A0.00Gap Down
ROSGQ
Rosetta Genomics
0.0$0.07+3.7%$119,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02+30.0%$118,000.00$20,000.000.00Gap Down
PZRXQ
PhaseRx
0.2$0.01+21.7%$108,000.00N/A0.00Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01+26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00+150.0%$81,000.00N/A0.00Gap Up
ALSE
Alseres Pharmaceuticals
0.0$6.00+0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00+0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02+1.6%$9,000.00$110,000.000.00
Acusphere logo
ACUS
Acusphere
0.0$0.03+1.8%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.09+8.1%$0.00N/A0.00High Trading Volume
Gap Up
AOBI
American Oriental Bioengineering
0.4$1.50+158.7%$0.00N/A0.00Gap Up
ARYX
ARYx Therapeutics
0.0$0.02+27.3%$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01+14.8%$0.00N/A0.00Gap Up
CBPI
China Botanic Pharmaceutical
0.0$0.07+0.0%$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01+0.0%$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.49+50.8%$0.00$9.93 million8.13Gap Down
DDXSQ
Diadexus
0.0$0.00+0.0%$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04+14.3%$0.00N/A0.00Gap Down
FTCY
Global Future City
0.5$0.05+1.8%$0.00N/A0.00High Trading Volume
GLSI
Greenwich LifeSciences
1.7$53.60+5.8%$0.00N/A0.00High Trading Volume
Gap Down
HRBR
Harbor Diversified
0.0$1.12+4.5%$0.00$263.61 million0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.